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ARTICLE
Late-onset Pompe disease: what is the 
prevalence of limb-girdle muscular 
weakness presentation?
Doença de Pompe de início tardio: qual é a prevalência na apresentação de fraqueza 
muscular de cinturas?
Paulo José Lorenzoni1, Cláudia Suemi Kamoi Kay1, Nádia Sugano Higashi1, Vânia D’Almeida2, Lineu Cesar 
Werneck1, Rosana Herminia Scola1
Pompe disease (PD), or glycogen storage disease type II, 
is a rare inherited autosomal recessive disease caused by a 
deficiency in acid alpha-glucosidase (GAA) enzyme leading 
to lysosomal glycogen storage1,2. Pompe disease can be diag-
nosed by measuring GAA levels or by identifying pathogenic 
variants in the GAA gene1,2. The late-onset phenotype results 
from an incomplete GAA deficiency, which appears later in 
childhood, in adolescence or in adulthood. The diagnosis 
of late-onset Pompe disease (LOPD) is still challenging and 
often quite delayed. It is not unusual for patients to go undi-
agnosed for many years as screening for PD is often over-
looked or delayed in adults2,3,4,5,6,7,8.
The clinical manifestation and laboratory findings vary 
with age and the degree of enzyme deficiency and, in some 
cases, the clinical presentation can mimic other neuromuscu-
lar disorders, such as limb-girdle muscular dystrophy (LGMD), 
often causing a significantly delayed diagnosis2,3,5,6,7,8,9. In this 
situation, muscle biopsy can help differentiate between these 
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ABSTRACT
Pompe disease is an inherited disease caused by acid alpha-glucosidase (GAA) deficiency. A single center observational study aimed at 
assessing the prevalence of late-onset Pompe disease in a high-risk Brazilian population, using the dried blood spot test to detect GAA 
deficiency as a main screening tool. Dried blood spots were collected for GAA activity assay from 24 patients with “unexplained” limb-girdle 
muscular weakness without vacuolar myopathy in their muscle biopsy. Samples with reduced enzyme activity were also investigated for 
GAA gene mutations. Of the 24 patients with dried blood spots, one patient (4.2%) showed low GAA enzyme activity (NaG/AaGIA: 40.42; 
%INH: 87.22%). In this patient, genetic analysis confirmed two heterozygous mutations in the GAA gene (c.-32-13T>G/p.Arg854Ter). Our data 
confirm that clinicians should look for late-onset Pompe disease in patients whose clinical manifestation is an “unexplained” limb-girdle 
weakness even without vacuolar myopathy in muscle biopsy.
Keywords: glycogen storage disease type II; muscular weakness; muscle diseases.
RESUMO
A doença de Pompe é uma doença hereditária causada pela deficiência da enzima alfa-glicosidase ácida (GAA). Estudo observacional foi realizado, 
em um único centro, para determinar a prevalência da doença de Pompe de início tardio (LOPD) em uma população brasileira de alto risco, usando 
teste em gota seca (DBS) como ferramenta principal de triagem para detectar a deficiência da GAA. DBS foi coletado para avaliar a atividade da 
GAA em 24 pacientes com fraqueza muscular de cinturas “não explicada” sem miopatia vacuolar na biópsia muscular. As amostras com atividade 
enzimática reduzida foram também submetidas a análise de mutações no gene GAA. Dos 24 pacientes com DBS, baixa atividade da enzima 
GAA (NaG/AaGIA: 40.42; %INH: 87.22%) foi encontrada em um paciente (4.2%). Nessa paciente, a análise genética confirmou duas mutações 
em heterozigose composta no gene GAA (c.-32-13T > G/p.Arg854Ter). Nossos resultados confirmam que LOPD deve ser investigada quando a 
manifestação clínica é uma fraqueza muscular de cinturas “não explicada”, mesmo na ausência de miopatia vacuolar na biópsia muscular.  
Palavras-chave: doença de depósito de glicogênio tipo II; debilidade muscular; doenças musculares.
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diseases because PD is usually associated with vacuolar myop-
athy with glycogen storage and the increased activity of acid 
phosphatase1,10. However, in some LOPD patients, the classical 
features are not present in the muscle biopsy because the adult 
form of the disease demonstrates fewer or no muscle fibers 
with vacuoles compared to the infantile or childhood forms; 
therefore, these patients may be erroneously diagnosed1,3,5,9,10.  
The main objective of this study was to assess the preva-
lence of LOPD in a high-risk Brazilian population with “unex-
plained” limb-girdle muscular weakness, using the dried blood 
spot (DBS) test as a screening tool to detect a GAA deficiency.
METHODS
All the patients were recruited from the outpatient clinic of a 
single neuromuscular disorder center at the Hospital de Clínicas 
of the Federal University of Paraná (Curitiba, Brazil). The inclu-
sion criteria for selected patients were limb-girdle muscle weak-
ness, muscle biopsy with the absence of vacuolar myopathy, no 
affected relatives and no definitive diagnosis of limb-girdle mus-
cular weakness. We excluded patients with a confirmed diag-
nosis of other neuromuscular diseases, patients with relatives 
diagnosed with PD, with relatives with known neuromuscular 
disorders, or patients younger than 18 years old. All studies were 
conducted in accordance with ethical principles after obtaining 
patient consent in the outpatient clinic.
Relevant data, including age, gender, serum creatine 
kinase (CK) levels, electromyographic findings and mus-
cle histopathology were recorded at the investigation of 
limb-girdle muscular weakness. 
Muscle biopsies were performed on the quadriceps or 
biceps brachialis muscles. The muscle biopsy samples were 
frozen in liquid nitrogen. Fresh frozen cryostat sections 
were stained using histology and histochemistry according 
to standard procedures11. Immunohistochemistry was per-
formed for dystrophin, dysferlin, sarcoglycans and caveolin-3.
Blood samples were collected from peripheral veins in 
heparin-coated vacuum tubes, and the blood was imme-
diately spotted onto filter paper (Whatman® 903). The GAA 
enzyme activity in the DBS was assayed according to stan-
dard procedures adapted from the method described 
by Chamoles et al.13 apud Müller et al.12 and Turaça et al.14. 
The main difference in the technique was that we used acar-
bose to inhibit the total GAA activity12. Enzymatic activities 
were expressed as the ratio of neutral and acid lysosomal 
isoforms (NaG/AaGIA) and the inhibition percentage of the 
total acid fraction (%INH). The ratio between acid and neu-
tral alpha-glucosidase isoforms was used to separate the 
true-positive from false-positive cases. The previously estab-
lished values within 95% confidence interval (CI), such as 
deficient enzyme activity, were NaG/AaGIA > 40 and %INH > 
87%12. The results of NaG/AaGIA > 40 and %INH < 87 or NaG/
AaGIA < 40 and %INH > 87 were considerate undetermined 
(grey zone). When the results of this analysis were considered 
to indicate a deficiency of enzyme activity, a blood sample 
was obtained for a second test enzyme assay on blood lym-
phocytes and/or genetic analysis of the GAA gene.
The data were analyzed using descriptive statistical 
methods. Results are presented as mean (±SD) or median, 
as appropriate. Statistical significance was assessed by the 
Mann-Whitney test for continuous variables and the χ2-test 
for categorical variables. The statistical significance for all 
calculations was set at a p < 0.05 value with a 95% CI.
RESULTS
We found 24 patients with “unclassified” limb-girdle mus-
cular weakness in our center who were eligible for laboratory 
screening for LOPD. The sample population consisted of 24 
patients (nine females and 15 males), aged 18 to 72 years 
(median: 39 years; mean: 38.7 ± 19.1); age at onset varied 
between one and 57 years, with a mean of 21.8 ± 17.8 years; 
the duration of follow-up in our hospital varied between four 
and 34 years, with a mean of 14.1 ± 7.8 years (Table). 
Table. Characteristics of the patients studied with normal and 
deficient GAA activity.
Variable Normal GAA activity
Deficient 
GAA activity
Number of patients 23 1
Gender (F : M) 08:15 01:00
Age, years (mean ± SD; median) 39.0 ± 19.5; 42 55
Age at onset, years  
(mean ± SD; median) 21.7 ± 18.2; 19 25
Time of follow-up, years 
(mean ± SD; median) 14.3 ± 7.9; 15 1
Serum CK level, U/L  
(mean ± SD; median)
2315.0 ± 3032.4; 
1023 1,467
Needle electromyography
myopathic features 10 1
mixed features* 4 0
myotonic discharge 1 1
normal 9 0
Muscle biopsy features
type 1 and 2 fiber atrophy 2 0
type 1 fiber atrophy 0 1
type 2 fiber atrophy 4 0
recent and chronic denervation 3 0
chronic myopathy 5 0
active myopathy 4 0
chronic and active myopathy 2 0
myopathy with denervation 3 0
increased acid phosphatase 8 1
DBS analysis (mean ± SD; median)    
NaG/AaGIA ratio 16.1 ± 6.6; 14.6 40.4
%INH 76.7 ± 6.8; 76.7 87.2
GAA: acid alpha-glucosidase; F: female; M: male; CK: creatine kinase; 
NaG/AaGIA: ratio of neutral and acid lysosomal isoforms; %INH: inhibition 
percentage of the total acid fraction; DBS: dried blood spot; *myopathic and 
denervation; SD: standard deviation. 
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Serum CK levels were elevated in 19 patients and normal 
in the remaining five patients (mean: 2,240.5 ± 2,989.8 U/L; 
median: 970.5 U/L; range: 85.0 to 12,610.0 U/L) (Table). 
The needle electromyographic pattern showed myopathic 
features in 11 patients, mixed features (myopathic and dener-
vation) in four patients, and was normal in the remaining nine 
patients. Myotonic discharge occurred in two patients (Table).
In muscle biopsy, the abnormalities found were: type 1 and 
2 fiber atrophy (2), type 1 fiber atrophy (1), type 2 fiber atro-
phy (4), recent and chronic denervation (3), chronic myopathy 
(5), active myopathy (4), chronic and active myopathy (2), and 
myopathy with denervation features (3) (Table). Muscle biopsy 
abnormalities were associated with increased acid phospha-
tase activity in muscle fibers in nine patients (Table). 
Dried blood spot analysis for GAA activity revealed nor-
mal values for the NaG/AaGIA ratio (mean: 16.1 ± 6.6; median: 
14.3; range: 6.7 to 37.3) and %INH (mean: 76.7% ± 6.8%; median: 
76.7%; range: 58.1% to 85.0%) in 23 patients (95.8%) (Table). 
Deficient GAA activity (NaG/AaGIA: 40.4; %INH: 87.2%) was 
detected in only one patient (4.2%) (Table). Patients with unde-
termined results (grey zone) in the DBS test were not found in 
our samples. Figure 1 shows the enzyme activity in all patients.
Statistical significance was found when GAA activity 
was deficient (p = 0.019). There is no statistical significance 
between patients with normal and deficient GAA activity for 
the remaining data.
The description of the one confirmed LOPD patient is as 
follows: The affected patient in our study was a 55-year-old 
woman (African descendant) who presented with mild myalgia 
and proximal lower limb weakness, and reported falls occurring 
mainly when walking for long distances, and difficulty climb-
ing stairs since the age of 25 years. She had mild dysphagia after 
the age of 50 years. There were no delayed motor milestones or 
relatives with similar symptoms. She had hypertension, diabe-
tes and dyslipidemia. Neurological examination showed normal 
Mini-Mental State Examination score (27/30), calf pseudohyper-
trophy, mild symmetrical weakness in proximal muscles in the 
lower limbs (Medical Research Council grade 4); axial muscle 
weakness in Gowers’ maneuver, diffusely reduced deep tendon 
reflexes, and a myopathic gait. The initial diagnosis was LGMD 
and the investigation yielded the following results: increased 
serum CK levels (1,467U/L; normal: ≤ 200U/L); needle electro-
myography revealed motor unit potentials with low amplitude 
and short duration in the iliopsoas muscle associated with fibril-
lation and short myotonic discharge potentials in lumbar para-
spinal muscles; the next generation sequencing customized 
panel for the main genes related to LGMD was negative; and 
muscle biopsy showed mild type 1 muscle fiber atrophy asso-
ciated with increased acid phosphatase activity in some mus-
cle fibers (Figure 2). She was diagnosed as “unclassified” LGMD. 
Follow-up investigation revealed a deficiency in the activity of 
the GAA enzyme (NaG/AaGIA ratio: 40.4%; %INH: 87.2%), which 
was also confirmed in another fluorimetric assay in the same 
sample (1.86umol/L/h; normal: > 4.0 umol/L/h) and in a second 
sample (0.88 mcmol/20H/L; normal: 8.53-35.40 mcmol/20H/L). 
She underwent targeted gene sequencing (next generation 
sequencing) for the GAA gene, which revealed two pathogenic 
variants (compound heterozygous): the c.-32-13T>G variant 
in the splice site of intron 1 and the c.2560C>T (p.Arg854Ter/
R854X) nonsense variant in exon 18. We diagnosed LOPD based 
Figure 1. Acid alpha-glucosidase (GAA) activities of the patients studied were expressed as the ratio of neutral and acid lysosomal 
isoforms (NaG/AaGIA) and the inhibition percentage of the total acid fraction (%INH). The line indicates the values established, 
such as deficient enzyme activity. 
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on clinical data and laboratory screening, which was confirmed 
by genetic analysis as well. She does not currently use enzyme 
replacement therapy. In the follow-up, other family members 
were also screened for GAA deficiency and one sister was diag-
nosed as LOPD, based on a deficiency of GAA activity and patho-
genic variants in the same compound heterozygous pattern (c.-
32-13T>G/p.Arg854Ter) detected in the GAA gene. 
DISCUSSION
Muscle biopsy is still performed in the investigation of the 
main differential diagnosis of limb-girdle muscular weakness, 
and a PD diagnosis is considered when vacuolar myopathy with 
glycogen accumulation, associated with increased acid phos-
phatase activity (lysosomal dysfunction), either in vacuoles or 
focal areas, is found1,4,9. However, muscle biopsy abnormalities in 
PD vary with the level of GAA deficiency, the clinical type (which 
is also related to the enzyme level) and the disease duration1,10. 
In LOPD, vacuole frequency has been reported to range from 
10% to 50% of patient fibers1,10. However, muscle biopsy can 
also present with less than 1% or no vacuolated fibers1,3,5,9,10,15. 
In these cases, an LOPD diagnosis may be overlooked. These 
reports motivated us to investigate LOPD in patients without 
vacuolated fibers in muscle biopsy, who were previously diag-
nosed with “unexplained” limb-girdle muscular weakness. 
Even though our patient did not have vacuolar myopa-
thy, her muscle biopsy showed mild non-dystrophic features 
(type 1 muscle fiber atrophy) associated with lysosomal dys-
function, which suggested the need to consider LOPD in the 
differential diagnosis. 
In recent years, the use of the DBS test has made the 
diagnostic procedure easier and cheaper. The test has good 
sensitivity and specificity, regardless of the different meth-
ods used4,12,13,15,16,17. The DBS is a simple screening test that 
has been suggested as the first step for the diagnosis of 
LOPD5,10,15,16. In our study, the DBS assay was useful in the 
LOPD diagnosis. To make sense of the diagnosis, the DBS test 
should be used in the screening of “unexplained” limb-girdle 
muscular weakness and “undetermined” myopathy. If screen-
ing with the DBS test is abnormal, confirmation of the diag-
nosis of LOPD must be achieved by means of enzymatic 
activity in isolated lymphocytes or analysis of the GAA gene.
An early PD diagnosis is essential because GAA enzyme 
replacement therapy is available nowadays and there is evi-
dence to suggest that treatment should be started early to get 
the best effect. However, LOPD is typically diagnosed years 
after the onset of initial symptoms5,9. The prevalence of undi-
agnosed LOPD in patients with “unclassified” LGMD and/or 
hyperCKemia varies from 0.8% to 4.6% in different countries, 
with a combined prevalence of 2.5%.3,4,5,6,7,8,10,15,16 The pediat-
ric population with limb-girdle muscular weakness and/or 
hyperCKemia has been screened for PD by DBS as well17.
In patients with “unclassified” LGMD, the prevalence 
of undiagnosed LOPD varies from 2% to 8% in European 
cohorts3,5,6,8,15,18. However, in some countries, e.g. Finland, 
undiagnosed LOPD was not found during the screening of 
Figure 2. Muscle biopsy from the LOPD patient shows no 
vacuolated muscle fibers associated with increased acid 
phosphatase activity in muscle fibers (A: Hematoxylin-eosin 
stain; B: Periodic acid-Schiff stain; C: Acid phosphatase stain). 
Bar = 50um.
A
B
C
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“undetermined” myopathy19. The prevalence varies between 
countries, probably reflecting the frequency of LOPD for each 
country3,6,8,10,15,16,17,18,19. Our study estimates the prevalence of 
undiagnosed LOPD to be 4.2% in southern Brazilian patients 
with “unexplained” limb-girdle weakness, from our centre. 
Screening for LOPD has also been performed in patients with 
either unexplained serum CK elevation, unexplained myopathy 
on muscle biopsy or restrictive respiratory insufficiency3,5,6,8,16,19. 
However, LOPD was more rare in these groups than in patients 
with “unclassified” LGMD, varying from 0.35% to 2.5%3,5,6,8,15.
Genetic analysis confirmed two pathogenic variants in 
the GAA gene in our patient. The mutation c.-32-13T>G is 
by far the most frequent worldwide pathogenic variant in 
the GAA gene and the R854X is a well-documented African–
American mutation8,10,14,20. Both mutations were previously 
reported in association with PD in Brazilian patients14,20. 
Recently, some studies have proposed using next genera-
tion sequencing to screening PD in patients with limb-girdle 
muscular weakness as it is faster and more cost-effective than 
Sanger sequencing2,14. Although more studies need to be per-
formed to establish its place in the investigation of LOPD, next 
generation sequencing has the advantage of diagnosing other 
causes of limb-girdle muscular weakness as well. However, 
the DBS test for GAA is a reliable diagnostic procedure that is 
noninvasive, easier, faster and cheaper, and is still considered a 
helpful tool as the first line screening specific for PD.  
Our study was limited by the small number of patients 
and regional data collection from southern Brazil. Studies on 
PD are not very common in Brazil. We believe that is neces-
sary to extend this type of study to many more clinical cen-
ters to further quantify the prevalence of undiagnosed LOPD 
in the Brazilian population. 
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